Abstract:Background Oncolytic virotherapy has become an important branch of cancer immunotherapy. This study investigated the efficacy of an oncolytic adenovirus (OAV), OncoViron, with synergistic mechanisms in the treatment of multiple solid tumors. Methods An OAV, OncoViron, was constructed and investigated by cytological experiments and implanted tumor models of multiple solid tumor cell lines to certify its anticancer efficacy, the synergistic effects of viral oncolysis and transgene anticancer activity of OncoViron, as well as oncolytic virotherapy combined with immunotherapy, were also verified. Results The selective replication of OncoViron mediated high expression of anticancer factors, specifically targeted a variety of solid tumors and significantly inhibited cancer cell proliferation. On a variety of implanted solid tumor models in immunodeficient mice, immunocompetent mice, and humanized mice, OncoViron showed great anticancer effects on its own and in combination with programmed death 1 (PD-1) antibody and chimeric antigen receptor (CAR) T cells. Pathological examination, single-cell sequencing, and spatial transcriptome analysis of animal implanted tumor specimens confirmed that OncoViron significantly altered the gene expression profile of infected cancer cells, not only recruiting a large number of lymphocytes, natural killer cells, and mononuclear macrophages into tumor microenvironment (TME) and activated immune cells, especially T cells but also inducing M1 polarization of macrophages and promoting the release of more immune cytokines, thereby remodeling the TME for coordinating PD-1 antibody or CAR T therapy. Conclusions The chimeric OncoViron is a novel broad-spectrum anticancer product with multiple mechanisms of synergistic and potentiated immunotherapy, creating a good opportunity for combined immunotherapy against solid tumors.

Virus-Protein Corona Replacement Strategy to Improve the Antitumor Efficacy of Intravenously Injected Oncolytic Adenovirus

Antigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy

Efficacy and Safety of Oncolytic Virus Immunotherapy in Advanced Malignancies: A Systematic Review of 161 Clinical Studies

Oncolytic Adenovirus: Prospects for Cancer Immunotherapy

Full Encapsulation of Oncolytic Virus Using Hybrid Erythroctye-Liposome Membranes for Augmented Anti-Refractory Tumor Effectiveness

Progress in oncolytic viruses modified with nanomaterials for intravenous application

Engineering Oncolytic Adenoviruses with VSVG‐Decorated Tumor Cell Membranes for Synergistically Enhanced Antitumor Therapy

Oncolytic Adenoviruses Expressing Checkpoint Inhibitors for Cancer Therapy.

Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors with Low Coxsackie and Adenovirus Receptor.

High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment

Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens.

Tumor Cell Membrane Biomimetic Liposomes-Coated Oncolytic Viruses to Target the Homotypic Tumor and Augment the Antitumor Efficacy

Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors

Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy

Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus

Oncolytic Adenovirus Programmed by Synthetic Gene Circuit for Cancer Immunotherapy

Oncolytic Virotherapy in Hepato‐bilio‐pancreatic Cancer: the Key to Breaking the Log Jam?

[Advances in research on oncolytic adenoviruses in tumor therapy]

The investigation of oncolytic viruses in the field of cancer therapy

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

Boarding Oncolytic Viruses onto Tumor-Homing Bacterium-Vessels for Augmented Cancer Immunotherapy